A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
PHASE2
This phase 2b study will evaluate the efficacy and safety of 16 and 24 week...
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
N/A
This Registry is designed to obtain long term data on participants who have...
Status
Completed
Location
Birmingham Gastroenterology Associates
Start Date
2011-12-19
Trial ID
NCT01457768
Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection
PHASE2
This is a Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Eval...
This Registry is designed to provide long term clinical and virologic follo...
Status
Completed
Location
Birmingham Gastroenterology Associates
Start Date
2012-04-13
Trial ID
NCT01457755
Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis
PHASE2
This study is to evaluate the antiviral efficacy, safety, and tolerability ...
A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection
N/A
The primary objective of this registry study is to assess the durability of...
GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype
PHASE2
This is a Phase 2, randomized, open-label exploratory study that will exami...